Abstract
In this double blind randomized study we compared the insulinkinetic, insulindynamic and the frequency of hypoglycemic events after s.c. injection of human insulin and the insulin analogue (B28Asp). Fourteen c-peptide negative patients treated with continuous subcutaneous insulin infusion (CSII) were included in the study. Their mean age was 42.9 (range 26 - 60 yrs), duration of diabetes 18.5 (5 - 29) and mean duration of CSII 6.3 yrs (3 - 10). Serum free insulin (FIRI) was determined from 8:00 to 11:00 h, and blood glucose from 7:00 to midnight. Maximum FIRI values were obtained after 45 min for (B28Asp) and after 90 min for Actrapid HM®. Maximum blood glucose increase (Tmax) was obtained 60 min after injection of (B28Asp) and 90 min after Actrapid HM®. The AUCBC was greater after administration of Actrapid HM® compared to (B28Asp) (p ≤ 0.05). A total number of 16 hypoglycemias (BG ≤ 3.3 mmol · l-1) were registered. 8 episodes were induced equally by (B28Asp) and by Actrapid HM®. We conclude that in insulin dependent diabetic patients the insulin analogue (B28Asp) showed a faster absorption and less hyperinsulinemia than Actrapid HM® after s.c. administration. The corresponding BG- values were higher after s.c. administration of Actrapid HM® compared to (B28Asp). These findings in patients support the concept of a more physiological effect of rapid acting insulin analogues than of regular insulin.
Key words
Insulin Analogues - Insulinkinetic - Insulin Dependent Diabetic Patients - CSII
